At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE
In Brief
A Phase 4 clinical trial evaluating Precision Antiplatelet Therapy Trial Group and Traditional Antiplatelet Therapy Control Group for Ischemic Stroke and Antiplatelet Drug. Completed, enrolled 1,224 participants across 1 site.
Detailed Summary
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.
Study Details
Timeline
Arms & Interventions
Platelet function testing guides antiplatelet drug selection
Aspirin 100mg orally once a day
Interventions
Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.